{"id":21475,"date":"2025-01-14T14:31:24","date_gmt":"2025-01-14T06:31:24","guid":{"rendered":"https:\/\/flcube.com\/?p=21475"},"modified":"2025-03-03T15:29:48","modified_gmt":"2025-03-03T07:29:48","slug":"3sbio-acquires-licensing-rights-to-duality-biologics-her2-targeting-adc-db-1303","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21475","title":{"rendered":"3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303"},"content":{"rendered":"\n

China-based 3SBio Inc. (HKG: 1530<\/a>) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics’ promising ADC, DB-1303, which targets the HER2 protein.<\/p>\n\n\n\n

Agreement Details<\/strong>
Pursuant to the agreement, 3SBio secures the commercialization rights to DB-1303 for multiple indications across mainland China, Hong Kong, and Macau. In return, Duality Biologics will receive an undisclosed upfront payment, as well as development and sales milestone payments. Duality Biologics will maintain responsibility for the ongoing clinical development and regulatory filings of DB-1303 within the specified territories, ensuring the product’s progress towards market readiness.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a…<\/p>\n","protected":false},"author":1,"featured_media":21476,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,35,232,3795,1061],"class_list":["post-21475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-3sbio","tag-adc-xdc","tag-duality-biologics","tag-duality-biotherapeutics","tag-hkg-1530"],"yoast_head":"\n3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21475\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303\" \/>\n<meta property=\"og:description\" content=\"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21475\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T06:31:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:29:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"617\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303\",\"datePublished\":\"2025-01-14T06:31:24+00:00\",\"dateModified\":\"2025-03-03T07:29:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475\"},\"wordCount\":129,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1402.png\",\"keywords\":[\"3SBio\",\"ADC \\\/ XDC\",\"Duality Biologics\",\"Duality Biotherapeutics\",\"HKG: 1530\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21475#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21475\",\"name\":\"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1402.png\",\"datePublished\":\"2025-01-14T06:31:24+00:00\",\"dateModified\":\"2025-03-03T07:29:48+00:00\",\"description\":\"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21475\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1402.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1402.png\",\"width\":1080,\"height\":617,\"caption\":\"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21475#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303 - Insight, China's Pharmaceutical Industry","description":"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21475","og_locale":"en_US","og_type":"article","og_title":"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303","og_description":"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.","og_url":"https:\/\/flcube.com\/?p=21475","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-14T06:31:24+00:00","article_modified_time":"2025-03-03T07:29:48+00:00","og_image":[{"width":1080,"height":617,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21475#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21475"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303","datePublished":"2025-01-14T06:31:24+00:00","dateModified":"2025-03-03T07:29:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21475"},"wordCount":129,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21475#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","keywords":["3SBio","ADC \/ XDC","Duality Biologics","Duality Biotherapeutics","HKG: 1530"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21475#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21475","url":"https:\/\/flcube.com\/?p=21475","name":"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21475#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21475#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","datePublished":"2025-01-14T06:31:24+00:00","dateModified":"2025-03-03T07:29:48+00:00","description":"China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a leading antibody conjugate drug (ADC) developer with operations in the United States and China. The collaboration centers on the licensing rights to Duality Biologics' promising ADC, DB-1303, which targets the HER2 protein.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21475#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21475"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21475#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","width":1080,"height":617,"caption":"3SBio Acquires Licensing Rights to Duality Biologics' HER2-Targeting ADC DB-1303"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21475#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1402.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21475"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21475\/revisions"}],"predecessor-version":[{"id":21477,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21475\/revisions\/21477"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21476"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}